In a patient with a 6.2 cm hepatic lesion showing neovascularization and a liver measuring 18.1 cm, what is the recommended diagnostic work‑up and management?

Management of 6.2 cm Hypervascular Hepatic Lesion

This 6.2 cm liver lesion with neovascularization requires immediate multiphase contrast-enhanced CT or MRI to establish whether this represents hepatocellular carcinoma (HCC) versus another diagnosis, followed by staging and treatment planning based on the Barcelona Clinic Liver Cancer (BCLC) system if HCC is confirmed.

Diagnostic Work-Up

Immediate Imaging Assessment

The presence of neovascularization in a 6.2 cm lesion is highly concerning for malignancy, particularly HCC. Non-invasive diagnosis requires state-of-the-art dynamic imaging with either multiphase multidetector CT or dynamic contrast-enhanced MRI to identify the typical vascular hallmark of HCC: hypervascular appearance in the arterial phase with washout in the portal venous or delayed phases 1.

• If cirrhosis is present: Non-invasive radiological criteria can establish HCC diagnosis without biopsy when the typical enhancement pattern is present 2
• If no cirrhosis: Pathological confirmation via biopsy is mandatory before treatment 2

Critical Clinical Information Needed

Determine immediately:

• Presence of chronic liver disease: Check for cirrhosis, hepatitis B/C status, alcohol history, metabolic syndrome
• Liver function: Child-Pugh score (albumin, bilirubin, INR, ascites, encephalopathy)
• Performance status: ECOG score
• Portal hypertension indicators: Platelet count, splenomegaly, varices on endoscopy 1
• Tumor markers: Alpha-fetoprotein (AFP) level 1

Staging Evaluation

Once HCC is suspected or confirmed:

• Chest CT to evaluate for pulmonary metastases
• Complete abdominal imaging to assess:
  • Number and size of all hepatic lesions
  • Macrovascular invasion (portal vein, hepatic veins)
  • Extrahepatic spread
  • Lymph node involvement 1

Management Algorithm Based on Clinical Scenario

Scenario 1: Single 6.2 cm Lesion in Non-Cirrhotic Liver

Surgical resection is the treatment of choice, provided R0 resection can be achieved without causing postoperative liver failure 1. The liver size of 18.1 cm suggests adequate liver volume for resection with sufficient remnant.

• Postoperative mortality should be <5% in experienced centers 1
• Pathological confirmation will be obtained from resection specimen
• No neo-adjuvant or adjuvant therapy is recommended 1

Scenario 2: Single 6.2 cm Lesion in Cirrhotic Liver (BCLC Stage A)

Treatment depends critically on liver function and portal hypertension status:

If Child-Pugh A with no clinically significant portal hypertension:

• Surgical resection is preferred if technically feasible 1
• Postoperative mortality <5% expected 1

If Child-Pugh A/B with portal hypertension OR not resection candidate:

• Consider liver transplantation if within Milan criteria (single lesion <5 cm) - but at 6.2 cm, this exceeds standard criteria 1
• TACE (transarterial chemoembolization) is the alternative, particularly with doxorubicin-eluting beads 1

If Child-Pugh B (score ≥8) or C:

• Not a resection candidate
• Evaluate for transplantation if otherwise eligible
• TACE may be considered for Child-Pugh B with good performance status 1

Scenario 3: Multiple Lesions or Advanced Disease

If multinodular disease (BCLC Stage B):

• TACE is the recommended treatment for patients with preserved liver function, no macrovascular invasion, and no extrahepatic spread 1
• Selective administration with doxorubicin-eluting beads preferred 1

If macrovascular invasion or extrahepatic spread (BCLC Stage C):

• Systemic therapy with sorafenib (or newer agents like atezolizumab/bevacizumab per current practice) for well-preserved liver function 1
• TACE contraindicated with macrovascular invasion 1

Critical Pitfalls to Avoid

1. Do not perform biopsy if planning resection in a resectable candidate - risk of tumor seeding (0-11%) and unnecessary delay 1

2. Do not use RFA for this size lesion - RFA is only appropriate for lesions ≤5 cm and ideally ≤3 cm 1. At 6.2 cm, RFA would have inadequate local control.

3. Do not rely on single-phase imaging - multiphase technique is essential for accurate diagnosis 1

4. Do not assume benign disease - while hemangiomas are common benign lesions, a 6.2 cm lesion with neovascularization requires definitive characterization, especially if there's any risk factor for HCC 3

5. Assess liver function before any treatment decision - even a single large lesion may not be resectable if liver function is inadequate 1

Biopsy Indications

Biopsy should be performed if:

• Non-invasive imaging criteria are not met (atypical enhancement pattern)
• Patient is non-cirrhotic (diagnosis requires pathology) 2
• Systemic therapy is being considered 2
• Differential diagnosis includes cholangiocarcinoma or metastasis

Biopsy should NOT be performed if:

• Patient is a clear resection candidate with typical imaging findings
• Patient has decompensated cirrhosis on transplant waiting list
• Patient is not a candidate for any therapy due to comorbidity 1

Multidisciplinary Discussion Required

Given the size and complexity, this case mandates discussion with:

• Hepatobiliary surgeon (resection feasibility)
• Transplant surgeon (if cirrhotic)
• Interventional radiologist (TACE option)
• Medical oncologist (systemic therapy if advanced)
• Hepatologist (liver function optimization)

The 18.1 cm liver size is relatively small (normal is approximately 20-22 cm in craniocaudal dimension), which may indicate underlying liver disease or simply individual variation, but this should be factored into surgical planning regarding adequate future liver remnant.